Korpershoek Esther, Petri Bart-Jeroen, van Nederveen Francien H, Dinjens Winand N M, Verhofstad Albert A, de Herder Wouter W, Schmid Sonja, Perren Aurel, Komminoth Paul, de Krijger Ronald R
Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center Rotterdam, JNI room 222, PO Box 2040, 3000 CR Rotterdam, The Netherlands.
Endocr Relat Cancer. 2007 Jun;14(2):453-62. doi: 10.1677/ERC-06-0044.
Pheochromocytomas (PCCs) are rare tumors that arise from chromaffin tissue in the adrenal medulla, but can also occur in the abdomen outside the adrenals and are then called sympathetic paragangliomas (sPGLs). According to the literature, between 15 and 25% of apparently sporadic adrenal PCC and sPGL are caused by germline mutations in RET, von Hippel-Lindau disease (VHL), succinate dehydrogenase subunit B (SDHB), or subunit D SDHD. However, few studies have addressed the mutationfrequency of these candidate genes in selected subgroups of PCC andsPGL, such as bilateral adrenal PCC or extra-adrenal sPGL, and none have looked at somatic mutations by analyzing tumor tissue. Therefore, we have investigated the occurrence of germline and somatic mutations in RET, VHL, SDHB, and SDHD in comparatively large series of bilateral adrenal PCC (n = 33 patients) and sPGL (n = 26 patients), with the aim of determining the mutation frequency of each of these genes and to establish a genetic testing algorithm. Twenty-one RET, two VHL germline, and one SDHD mutations were found in the patients with bilateral adrenal PCC. In sPGL, one novel SDHB germline and one novel SDHB somatic mutation were observed. In addition, two SDHD germline mutations were found. We conclude that germline RET mutations are predominantly found in bilateral PCC, and that somatic and germline SDHB and SDHD mutations usually occur in sPGL, which has practical consequences for genetic testing algorithms. We suggest that sequential mutation analysis should be directed first at RET, followed by VHL and SDHD for patients with bilateral adrenal PCC at diagnosis, and at SDHB and SDHD for patients with sPGL.
嗜铬细胞瘤(PCCs)是一种罕见肿瘤,起源于肾上腺髓质的嗜铬组织,但也可发生于肾上腺外的腹部,此时称为交感神经节旁神经瘤(sPGLs)。据文献报道,15%至25%的散发性肾上腺PCC和sPGL由RET、冯·希佩尔-林道病(VHL)、琥珀酸脱氢酶亚基B(SDHB)或亚基D(SDHD)的种系突变引起。然而,很少有研究探讨这些候选基因在PCC和sPGL特定亚组中的突变频率,如双侧肾上腺PCC或肾上腺外sPGL,且没有研究通过分析肿瘤组织来观察体细胞突变。因此,我们调查了相对大量的双侧肾上腺PCC(n = 33例患者)和sPGL(n = 26例患者)中RET、VHL、SDHB和SDHD的种系和体细胞突变情况,目的是确定每个基因的突变频率并建立遗传检测算法。在双侧肾上腺PCC患者中发现了21个RET、2个VHL种系和1个SDHD突变。在sPGL中,观察到1个新的SDHB种系和1个新的SDHB体细胞突变。此外,还发现了2个SDHD种系突变。我们得出结论,种系RET突变主要见于双侧PCC,而体细胞和种系SDHB及SDHD突变通常见于sPGL,这对遗传检测算法有实际影响。我们建议,对于诊断为双侧肾上腺PCC的患者,顺序突变分析应首先针对RET,其次是VHL和SDHD;对于sPGL患者,则针对SDHB和SDHD。